News
April 23, 2025
Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Read
January 9, 2025
Abdera Therapeutics to Present at the 43rd Annual J.P Morgan Healthcare Conference
Read
September 5, 2024
Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma
Read
August 5, 2024
Fierce Biotech Names Abdera Therapeutics a “Fierce 15” Biotech Company of 2024
Read
June 27, 2024
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
Read
May 23, 2024
Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
Read
January 30, 2024
Abdera Therapeutics Expands Management Team and Board of Directors
Read
April 20, 2023
Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
Read